A carregar...
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
OBJECTIVE: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple sclerosis improved the spasticity of patients previously treated with interferon-β. However, whether such an improvement was translated into cost savings remained unclear. We therefor...
Na minha lista:
| Publicado no: | Health Econ Rev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4608957/ https://ncbi.nlm.nih.gov/pubmed/26475277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-015-0066-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|